DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
about
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular diseaseDipeptidyl peptidase-4 and kidney fibrosis in diabetesDipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular DiseaseRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsAdipose tissue dysfunction as a central mechanism leading to dysmetabolic obesity triggered by chronic exposure to p,p'-DDE.Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarctionThe regulatory role of DPP4 in atherosclerotic disease.Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian SubjectsEffect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study.Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease.DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.Vascular Smooth Muscle as a Target for Novel Therapeutics.Dipeptidyl Peptidase-4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress.CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology.GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studiesInhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway.Impact of CD14++CD16+ monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study.Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.Chronic Psychological Stress Accelerates Vascular Senescence and Impairs Ischemia-Induced Neovascularization: The Role of Dipeptidyl Peptidase-4/Glucagon-Like Peptide-1-Adiponectin Axis.Role of Incretin Axis in Inflammatory Bowel Disease.New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.Inhibiting DPP4 in a mouse model of HHT1 results in a shift towards regenerative macrophages and reduces fibrosis after myocardial infarction.DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.Regulation of Dipeptidyl Peptidase IV in the Post-stroke Rat Brain and In Vitro Ischemia: Implications for Chemokine-Mediated Neural Progenitor Cell Migration and Angiogenesis.DPP4 regulates the inflammatory response in a rat model of febrile seizures.Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain.Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins.The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.Obesity parameters, physical activity, and physical fitness are correlated with serum dipeptidyl peptidase IV activity in a healthy population.In-Hospital Implementation of Evidence-Based Medications is Associated with Improved Survival in Diabetic Patients with Acute Coronary Syndrome - Data from TSOC ACS-DM Registry.
P2860
Q26741067-2D504F20-688A-4305-BEF7-16F198E8FC0DQ26766089-7AADC82E-00A9-4DA2-A856-236B9EC0AB45Q26781269-DFFFE2DD-A6AA-4E6E-8CA3-6C5FA76F1D6CQ28081569-DA1212E0-5EEC-4020-8B4F-8B2CEADB258DQ33752824-44F9AE7B-0E6E-4268-865E-DF03B559AC03Q33771334-A6661E79-6499-47AF-9FDF-8C56230A7415Q33805518-9ED0FC2F-CBFC-48B7-8B0C-5B8034807132Q35998458-3D865505-9A8E-41BE-83CB-A7C41F6D097CQ36119669-8F1489BF-5CFD-4CF0-9F64-68C9C9F9D4CCQ36139664-FEECF6E5-6D76-4E47-9B83-FF2EEAB22E20Q36338382-31992B8C-AB3B-4843-9E9D-DAF8466412CEQ36964223-6AA60AD4-30B0-45E7-A303-9F45B46A178BQ37337371-6983A5BB-E9F4-4665-A9B6-B3B2D8D2F03BQ37522403-58588CD2-C489-4F94-AC17-965CDDD9B64FQ38567506-A40ACB96-705A-4646-8E9C-C2A8A744601DQ38657340-9B59F027-DF2D-4679-B7E1-0ED5CA38C262Q38690194-34A74BBD-FC64-4517-A49D-73A76DEA616AQ38709406-A7A7DABD-DBC4-4F27-8E43-8265BB90117FQ38787756-5C669696-25F1-45EF-9C56-D208F8573BF8Q38820260-AB387599-2CCD-4D65-9EC0-9FD080B1C526Q38833312-0CD3C9A6-92F5-4A5A-9885-7C5BE13FDB36Q38912469-79BCC7B0-6CBF-493C-9DBF-8D6023612609Q41237048-2903A07E-FA85-44FA-BE6A-613C4A820454Q41318423-77DD202D-B993-475D-A06F-4683C2A66206Q43163467-28B6B199-0ECD-4644-9C77-856CC76FD1D1Q47099656-17C560BA-5C8C-412D-95CA-1A3D63D0239AQ47103249-FE233DC2-06FF-425E-8A39-BFF909D44CF2Q47113843-CC87C695-6415-4E36-83AD-1D7A3A38519CQ47138798-44397013-F647-416D-9D55-37DE9FB955DEQ47148482-6CD01C02-565A-4515-8C96-6DF934B6C16EQ47265349-0B26AE65-2940-46C5-AFB2-26C23B32FBAAQ48141985-1723B8B6-575A-410A-9FDA-44A4743109B1Q48570285-2207F135-6E31-4862-AA60-551F2FBB62B1Q51074054-23ED7C01-23A0-4ADC-AD4E-4ADE4A97517BQ51738629-361A99A0-32FF-4683-AE50-C88831153090Q52369966-B1DD7F89-3614-46C3-98B7-0DD666966F27Q52718518-C4B373B3-50AC-4179-8FAC-97578654E524Q53568958-BE2DC69B-7B8A-4AB4-9E13-657929A2A925Q54985577-00C954F9-4961-4A8C-8940-4457200974D5Q55045262-BDFD27C8-4B3E-487F-9F2B-E9B82C61D83E
P2860
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
DPP4 in cardiometabolic diseas ...... cal trials of DPP4 inhibition.
@en
type
label
DPP4 in cardiometabolic diseas ...... cal trials of DPP4 inhibition.
@en
prefLabel
DPP4 in cardiometabolic diseas ...... cal trials of DPP4 inhibition.
@en
P2860
P1433
P1476
DPP4 in cardiometabolic diseas ...... ical trials of DPP4 inhibition
@en
P2093
Sanjay Rajagopalan
Stephen N Davis
P2860
P304
P356
10.1161/CIRCRESAHA.116.305665
P577
2015-04-01T00:00:00Z